FKRCX
Price
$43.29
Change
+$2.37 (+5.79%)
Updated
Jul 2 closing price
Net Assets
2.97B
OGMNX
Price
$51.47
Change
+$2.00 (+4.04%)
Updated
Jul 2 closing price
Net Assets
3.54B
Interact to see
Advertisement

FKRCX vs OGMNX

FKRCX vs OGMNX Comparison Chart in %
View a ticker or compare two or three
VS
FKRCX vs. OGMNX commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FKRCX is a Hold and OGMNX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
OGMNX has more cash in the bank: 3.54B vs. FKRCX (2.97B). FKRCX pays higher dividends than OGMNX: FKRCX (11.95) vs OGMNX (0.32). FKRCX was incepted earlier than OGMNX: FKRCX (57 years) vs OGMNX (25 years). OGMNX (1.31) is less costly to investors than FKRCX (0.87). OGMNX is a more actively managed with annual turnover of: 47.00 vs. FKRCX (22.76). FKRCX (1000) and OGMNX (1000) have matching initial minimum investment requirements. FKRCX annual gain was more profitable for investors over the last year : 67.64 vs. OGMNX (45.90). FKRCX return over 5 years is better than : 155.08 vs. OGMNX (106.44).
FKRCXOGMNXFKRCX / OGMNX
Total Expense Ratio0.871.3166%
Annual Report Gross Expense Ratio0.871.3166%
Fund Existence57 years25 years-
Gain YTD-6.177-7.64481%
Front Load6%N/A-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets2.97B3.54B84%
Annual Yield % from dividends11.950.323,716%
Returns for 1 year67.6445.90147%
Returns for 3 years232.01139.04167%
Returns for 5 years155.08106.44146%
Returns for 10 years233.51200.89116%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NTST21.660.58
+2.75%
NetSTREIT Corp
SCI78.561.81
+2.36%
Service Corp
ALTO5.19N/A
N/A
Alto Ingredients
STRC74.57N/A
N/A
Strategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock
OACCU10.73N/A
N/A
Oaktree Acquisition Corp III Life Sciences